Related Experiment Videos
Acute interstitial nephritis due to mesalazine
Mario Tadic1, Ivica Grgurevic, Mira Scukanec-Spoljar
1Department of Internal Medicine, Dubrava University Hospital, Zagreb, Croatia. mtadic@kbd.hr
Nephrology (Carlton, Vic.)
|May 10, 2005
Summary
Mesalazine can cause acute interstitial nephritis (AIN), a kidney condition, in ulcerative colitis (UC) patients. Early detection and stopping mesalazine treatment are key to preventing permanent kidney damage.
Area of Science:
- Nephrology
- Gastroenterology
- Pharmacology
Background:
- Ulcerative colitis (UC) is an inflammatory bowel disease often treated with mesalazine.
- Acute interstitial nephritis (AIN) is a potential adverse drug reaction affecting kidney function.
- Mesalazine is a common medication used for managing UC.
Observation:
- A 41-year-old patient with UC presented with symptoms suggestive of AIN, including fever, arthralgia, eosinophilia, and renal failure.
- Renal biopsy confirmed the diagnosis of acute interstitial nephritis.
- The patient's condition improved after discontinuing mesalazine and receiving intravenous methylprednisolone.
Findings:
- Mesalazine was identified as the causative agent for acute interstitial nephritis in this UC patient.
- Withdrawal of mesalazine led to the recovery of renal function.
- Prompt treatment, including corticosteroid therapy, facilitated the amelioration of AIN.
Implications:
- This case highlights the importance of recognizing mesalazine-induced AIN in patients with UC.
- Routine monitoring of renal function is recommended for patients on mesalazine therapy.
- Early diagnosis and discontinuation of the offending drug are crucial to prevent chronic kidney disease.